Barinthus Biotherapeutics shows Oxford Science Enterprises plc at 0.0% ownership in a passive stake amendment, alongside a transaction involving 8,797,770 shares at $0.11 per share. The record gives investors both the reported ownership position and the transaction’s stated per-share value.
Key Highlights
- Oxford Science Enterprises plc is identified in a transaction involving 8,797,770 Barinthus shares at $0.11 per share.
- Oxford Science Enterprises’ amendment is dated 09/09/2026, while its signature is dated 09/11/2026.
- Oxford Science Enterprises plc reported 0.0% ownership of Barinthus Biotherapeutics plc.
- The passive stake amendment was filed under Rule 13d-1(d), with England, United Kingdom, listed as the jurisdiction.
Barinthus Biotherapeutics plc. is shown with a 0.0% position for Oxford Science Enterprises plc in a passive stake amendment.
Passive Stake Record Sets Out Ownership and Transaction Details
Oxford Science Enterprises plc appears as the reporting person under Rule 13d-1(d), with the amendment recording 0.0% ownership. The record identifies England, United Kingdom, as its Jurisdiction and dates the amendment 09/09/2026. Antonia Jenkinson signed for Oxford Science Enterprises in the capacity of chief financial officer on 09/11/2026. The transaction note identifies Oxford Science Enterprises as an insider of Barinthus Biotherapeutics and gives the per-share amount as $0.11.
FAQs
Q: What ownership percentage does Oxford Science Enterprises report in Barinthus Biotherapeutics?
A: Oxford Science Enterprises plc is listed at 0.0% ownership in the Barinthus Biotherapeutics passive stake amendment. The record identifies it as the reporting person.
Q: How many Barinthus Biotherapeutics shares were involved in the transaction?
A: It identifies the per-share amount as $0.11 and records Oxford Science Enterprises plc’s ownership as 0.0%.
Q: When was the Barinthus Biotherapeutics stake amendment dated?
A: The passive stake amendment is dated 09/09/2026. Oxford Science Enterprises’ chief financial officer, Antonia Jenkinson, signed the record on 09/11/2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.